News & Events about Roivant Sciences Ltd.
Globe Newswire
2 months ago
46.4% of subjects receiving VTAMA cream, 1% achieved the primary endpoint of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-ADTM) response of clear (0) or almost clear (1) with at least a 2-grade improvement from baseline at Week 8, versus 18.0% on vehicle (PAll secondary ...
Globe Newswire
2 months ago
PVTX-321 and PVTX-405 Achieve Development Candidate NominationNEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- Proteovant Therapeutics,aRoivant Sciences (Nasdaq: ROIV) company leveraging the process of protein degradation to discover and develop transformative medicines for the treatment of patients ...
Roivant Sciences Ltd. (NASDAQ:ROIV Get Rating) Director Vivek Ramaswamy sold 4,000,000 shares of the businesss stock in a transaction dated Wednesday, February 22nd. The shares were sold at an average price of $7.95, for a total value of $31,800,000.00. Following the completion of the transaction, ...
Globe Newswire
3 months ago
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that its founder Vivek Ramaswamy has stepped down from the companys board of directors to focus on his U.S. presidential campaign. Vivek founded Roivant in 2014 ...
Globe Newswire
3 months ago
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced the pricing of an upsized underwritten public offering of 26,666,666 of its common shares at a price to the public of $7.50 per share. All of the common shares to ...